title: Comparison of effects of nebivolol, carvedilol and irbesartan on left ventricular hypertrophy associated with hypertension.
abstract: OBJECTIVE
  The aim of this study was to investigate if the new generation beta-blockers are as effective as irbesartan, which is an angiotensin receptor blocker (ARB), on left ventricular hypertrophy (LVH).
  
  
  METHODS
  The study included 85 patients (average age: 56.6±9.6 year) with stage 1 and 2 hypertension, who previously didn't receive an antihypertensive treatment, but diagnosed with LVH echocardiographically. The patients were divided into three different treatment groups: irbesartan (n=28), nebivolol (n=25) and carvedilol (n=32). The patients were reassessed clinically and echocardiographically at 3, 6 and 12 months after the treatments.
  
  
  RESULTS
  There was no statistically significant difference in baseline left ventricular mass index (LVMI) and other parameters among the three treatment groups (p > 0.05). Although there was no significant decrease in LVMI in irbesartan and carvedilol groups at 3 months after the treatment (p > 0.05), the values measured at 6 and 12 months (p < 0.0001) were significant. The decrease in LVMI in the nebivolol group was significant at 3, 6 and 12 months (p < 0.0001). There was a significant difference in measurements at 12 months (p < 0.05).
  
  
  CONCLUSIONS
  Both of the new generation beta-blockers were more effective than irbesartan in the regression of LVH. A significant regression in LVH was observed 3 months after nebivolol treatment and 6 months after irbesartan and carvedilol treatments.
authors.affiliation: Department of Cardiology, Faculty of Medicine, Ataturk University, Erzurum, Turkey. husnudr1982@gmail.com.
authors.forename: H
authors.initials: H
authors.lastname: Degirmenci
authors.forename: M
authors.initials: M
authors.lastname: Açikel
authors.forename: E M
authors.initials: EM
authors.lastname: Bakirci
authors.forename: H
authors.initials: H
authors.lastname: Duman
authors.forename: S
authors.initials: S
authors.lastname: Demirelli
authors.forename: H
authors.initials: H
authors.lastname: Tas
authors.forename: Z
authors.initials: Z
authors.lastname: Simsek
authors.forename: S
authors.initials: S
authors.lastname: Karakelleoglu
authors.forename: E
authors.initials: E
authors.lastname: Aksakal
authors.forename: M K
authors.initials: MK
authors.lastname: Erol
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001713:Biphenyl Compounds; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D015331:Cohort Studies; D005260:Female; D006801:Humans; D006973:Hypertension / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000453:epidemiology; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000453:epidemiology; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol / Q000627:therapeutic use*; D011412:Propanolamines / Q000627:therapeutic use*; D011446:Prospective Studies; D013777:Tetrazoles; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D002227:Carbazoles; D011412:Propanolamines; D013777:Tetrazoles; D000068577:Nebivolol; D000077261:Carvedilol; D000077405:Irbesartan